The Dose-Response Relationship of Atomoxetine for the Treatment of Children With ADHD: A Systematic Review and Dose-Response Meta-Analysis of Double-Blind Randomized Placebo-Controlled Trials

Abstract

Objectives:

The present study aimed to meta-analytically estimate the dose-response relationship of atomoxetine for treating children with ADHD.

Methods:

We systematically searched double-blind randomized placebo-controlled trials that evaluated the effectiveness of atomoxetine for treating ADHD in children. The search was carried out in PubMed, Cochrane Library, CINHAL, and ClinicalTrials.gov databases, covering articles from their inception until January 20, 2023. In addition, a dose-response meta-analysis was conducted.

Results:

In this dose-response meta-analysis, 12 double-blind randomized placebo-controlled trials involving 2,250 patients were included. The efficacy of atomoxetine increased up to a dosage of 1.4 mg/kg, after which it reached a plateau.

Conclusions:

The first dose-response meta-analysis of atomoxetine dosing for children with ADHD conducted here enhances the robustness of the Food and Drug Administration and the European Medicines Agency dose recommendations.

Keywords

atomoxetine dose-response meta-analysis ADHD

Get full access to this article

View all access options for this article.

References

Brown

J. T.

Bishop

J. R.

Sangkuhl

Nurmi

E. L.

Mueller

D. J.

Dinh

J. C.

Gaedigk

Klein

T. E.

Caudle

K. E.

McCracken

J. T.

de Leon

Leeder

J. S.

(2019). Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clinical Pharmacology & Therapeutics, 106(1), 94–102.

Brown

R. T.

Perwien

Faries

D. E.

Kratochvil

C. J.

Vaughan

B. S.

(2006). Atomoxetine in the management of children with ADHD: Effects on quality of life and school functioning. Clinical pediatrics, 45(9), 819–827.

Catalá-López

Hutton

Núñez-Beltrán

Page

M. J.

Ridao

Macías Saint-Gerons

Catalá

M. A.

Tabarés-Seisdedos

Moher

(2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One, 12(7), e0180355.

Christman

A. K.

Fermo

J. D.

Markowitz

J. S.

(2004). Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy, 24(8), 1020–1036.

Cortese

Adamo

Del Giovane

Mohr-Jensen

Hayes

A. J.

Carucci

Atkinson

L. Z.

Tessari

Banaschewski

Coghill

Hollis

Simonoff

Zuddas

Barbui

Purgato

Steinhausen

H. C.

Shokraneh

Xia

Cipriani

(2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 5(9), 727–738.

Crippa

Discacciati

Bottai

Spiegelman

Orsini

(2019). One-stage dose-response meta-analysis for aggregated data. Statistical Methods in Medical Research, 28(5), 1579–1596.

Crippa

Orsini

(2016). Multivariate dose-response meta-analysis: The dosresmeta R Package. Journal of Statistical Software, Code Snippets, 72(1), 1–15 https://doi.org/10.18637/jss.v072.c01

The electronic medicines compendium. Emc. Retrieved March 2, 2022, from https://www.medicines.org.uk/emc/product/5531/smpc#gref

Erskine

H. E.

Norman

R. E.

Ferrari

A. J.

Chan

G. C.

Copeland

W. E.

Whiteford

H. A.

Scott

J. G.

(2016). Long-term outcomes of Attention-Deficit/Hyperactivity Disorder and conduct disorder: A systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55(10), 841–850.

10.

D. D.

Guo

H. L.

Y. H.

Xia

Fang

W. R.

Y. M.

Chen

Liu

Q. Q.

(2021). The mechanism, clinical efficacy, safety, and dosage regimen of atomoxetine for ADHD therapy in children: A narrative review. Frontiers in Psychiatry, 12, 780921.

11.

Gallezot

J. D.

Weinzimmer

Nabulsi

Lin

S. F.

Fowles

Sandiego

McCarthy

T. J.

Maguire

R. P.

Carson

R. E.

Ding

Y. S.

(2011). Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. Neuroimage, 56(1), 268–279.

12.

Gau

S. S.

Huang

Y. S.

Soong

W. T.

Chou

M. C.

Chou

W. J.

Shang

C. Y.

Tseng

W. L.

Allen

A. J.

Lee

(2007). A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 17(4), 447–460.

13.

Guyatt

G. H.

Oxman

A. D.

Vist

G. E.

Kunz

Falck-Ytter

Alonso-Coello

Schünemann

H. J.

(2008). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 336(7650), 924–926.

14.

Harrell

(2015). Regression modeling strategies, with applications to linear models, logistic and ordinal regression, and survival analysis. Springer.

15.

Hervas

Huss

Johnson

McNicholas

van Stralen

Sreckovic

Lyne

Bloomfield

Sikirica

Robertson

(2014). Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, phase III trial. European Neuropsychopharmacology, 24(12), 1861–1872.

16.

Higgins

Thomas

Chandler

Cumpston

Pag

Welch

(2022). Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). https://www.training.cochrane.org/handbook

17.

Institute for Health Metrics and Evaluation. (2019). Global health data exchange. Retrieved May 12, 2022, from https://vizhub.healthdata.org/gbd-results/

18.

Kelsey

D. K.

Sumner

C. R.

Casat

C. D.

Coury

D. L.

Quintana

Saylor

K. E.

Sutton

V. K.

Gonzales

Malcolm

S. K.

Schuh

K. J.

Allen

A. J.

(2004). Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics, 114(1), e1–e8.

19.

Kratochvil

C. J.

Vaughan

B. S.

Stoner

J. A.

Daughton

J. M.

Lubberstedt

B. D.

Murray

D. W.

Chrisman

A. K.

Faircloth

M. A.

Itchon-Ramos

N. B.

Kollins

S. H.

Maayan

L. A.

Greenhill

L. L.

Kotler

L. A.

Fried

March

J. S

. (2011). A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics, 127(4), e862–e868.

20.

Logan

Wang

G. J.

Telang

Fowler

J. S.

Alexoff

Zabroski

Jayne

Hubbard

King

Carter

Shea

Muench

Schlyer

Learned-Coughlin

Cosson

Volkow

N. D.

Ding

Y. S.

(2007). Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: Problems and progress. Nuclear Medicine and Biology, 34(6), 667–679.

21.

Martenyi

Zavadenko

N. N.

Jarkova

N. B.

Yarosh

A. A.

Soldatenkova

V. O.

Bardenstein

L. M.

Kozlova

I. A.

Neznanov

N. G.

Maslova

O. I.

Petrukhin

A. S.

Sukchotina

N. K.

Zykov

V. P.

(2010). Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: A 6-week, randomized, placebo-controlled, double-blind trial in Russia. European Child & Adolescent Psychiatry, 19(1), 57–66.

22.

Michelson

Allen

A. J.

Busner

Casat

Dunn

Kratochvil

Newcorn

Sallee

F. R.

Sangal

R. B.

Saylor

West

Kelsey

Wernicke

Trapp

N. J.

Harder

(2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159(11), 1896–1901.

23.

Michelson

Faries

Wernicke

Kelsey

Kendrick

Sallee

F. R.

Spencer

(2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108(5), E83.

24.

Newcorn

J. H.

Kratochvil

C. J.

Allen

A. J.

Casat

C. D.

Ruff

D. D.

Moore

R. J.

Michelson

(2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. American Journal of Psychiatry, 165(6), 721–730.

25.

R Core Team. (2021). R: A language and environment for statistical computing. https://www.R-project.org/

26.

Spencer

Heiligenstein

J. H.

Biederman

Faries

D. E.

Kratochvil

C. J.

Conners

C. K.

Potter

W. Z.

(2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63(12), 1140–1147.

27.

Stahl

S. M.

(2003). Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: Exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. The Journal of Clinical Psychiatry, 64(2), 110–111.

28.

Sterne

J. A. C.

Savović

Page

M. J.

Elbers

R. G.

Blencowe

N. S.

Boutron

Cates

C. J.

Cheng

H. Y.

Corbett

M. S.

Eldridge

S. M.

Emberson

J. R.

Hernán

M. A.

Hopewell

Hróbjartsson

Junqueira

D. R.

Jüni

Kirkham

J. J.

Lasserson

. . . Higgins

JPT

. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898.

29.

Sugimoto

Suzuki

Orime

Hayashi

Yoshinaga

Egawa

Ono

Sugai

Inoue

Someya

(2021). The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/hyperactivity disorder: A non-randomized prospective interventional study. Medicine (Baltimore), 100(27), e26552.

30.

Takahashi

Takita

Yamazaki

Hayashi

Ichikawa

Kambayashi

Koeda

Oki

Saito

Takeshita

Allen

A. J.

(2009). A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 19(4), 341–350.

31.

Takano

Gulyás

Varrone

Maguire

R. P.

Halldin

(2009). Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: A rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2). European Journal of Nuclear Medicine and Molecular Imaging, 36(8), 1308–1314.

32.

Weiss

Tannock

Kratochvil

Dunn

Velez-Borras

Thomason

Tamura

Kelsey

Stevens

Allen

A. J.

(2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 44(7), 647–655.

33.

G. F.

Markowitz

J. S.

(2016). Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. Journal of Child and Adolescent Psychopharmacology, 26(4), 314–326.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB

0.02 MB